Geroscience Biomarkers: Which metrics are supported—evidence status

Context: Why “measuring biological age” doesn’t automatically mean “getting biologically better”

Geroscience biomarkers aim to quantify biological aging processes indirectly—e.g., through epigenetic age or markers that reflect inflammation or disease burden. The key point is that correlations with age are not automatically surrogates for health. In the evidence base, there are marker groups with relatively solid support, but often limited clarity about which changes in measured values are clinically meaningful.

What Geroscience biomarkers are supposed to measure—and why lifestyle is often the bigger lever

Geroscience biomarkers usually measure molecular “footprints” of aging biology—but the step from marker shifts to health benefit is often not well established. That is why, in practice, lifestyle optimization (sleep, movement, light, nutrition) should be your first lever: many of these factors influence inflammatory and metabolic states that can appear across several marker families.

Geroscience biomarkers are not a single standardized measurement concept; they’re an umbrella term. In the study families discussed here, you mainly see three directions:

1. epigenetic aging (e.g., “epigenetic age” derived from DNA methylation),
2. epitranscriptomic markers (i.e., chemical modifications of RNA and their functional consequences; summarized in a review),
3. inflammation / multi-disease or multimorbidity signals, often appearing as clusters and reflecting “disease burden” more than “clock time.”

Important for interpretation: even if a marker reliably reflects aging processes, it is often still unclear whether a specific intervention shifts that marker in a health-relevant way. This is a methodological issue: many studies use surrogate endpoints, while clinical outcomes (e.g., functional performance, frailty progression, quality of life) are more complex and take longer.

Lifestyle typically affects multiple biological axes at once. So it is plausible that markers change without every marker change guaranteeing long-term health gains. This does not mean biomarkers are useless—rather, they should be treated as decision-support under uncertainty, not as an “anti-aging score” that replaces causality.

If you prioritize lifestyle as a lever, a general thinking model helps: first, stabilize the main behavioral and physiological pathways (e.g., circadian rhythm, sleep quality, physical activity). In particular, inflammatory status and metabolic markers are often modulated more favorably— even if the specific “Geroscience clock” in every RCT doesn’t tip in the size you expected. As background, you can also place this evidence logic in Meta-analyses: Evidence & what’s truly supported?.

Evidence hierarchy: From meta-analysis to pilot study—what is really strong?

The strongest evidence is provided by summaries that quantify relationships and compare results across study means (meta-analysis/systematic review). In the list you provided, the evidence is particularly “hard” for associations between genetic burden and older epigenetic age (Arpawong et al., 2023, PMID 37101297). For specific intervention effects on markers or health, there are RCTs and pilot studies—but generalizability remains limited.

A meta-analysis or systematic review is often the best starting point to judge how consistently a marker appears in a given question. Here’s the example Arpawong et al., 2023: the study examines ADHD genetic burden and its association with older epigenetic age, and discusses mediating roles of factors such as education and behavioral/sociodemographic variables (Arpawong et al., 2023, PMID 37101297). This does not provide an “anti-aging intervention guide,” but it shows that specific epigenetic aging measures measurably correlate with meaningful burden and life-context factors.

Systematic reviews also provide context for more complex mechanisms that are not simply “one marker = one outcome.” So Wagner et al., 2022 frames the Epitranscriptome in aging and in stress-resistance as a relevant—yet complex—marker/mechanism framework (Wagner et al., 2022, PMID 35908668). Work like this helps keep expectations realistic: epitranscription pathways are plausibly linked, but the evidence base is heterogeneous.

For interventions, the evidence is typically thinner because:

• markers are surrogates,
• follow-up periods are often too short for clinical effects,
• endpoints are operationalized differently.

Still, you have RCT-adjacent evidence in the list. Example: CALERIE Biobank Analysis uses RCT-context data on calorie restriction and analyzes how the rate of biological aging might change under restriction (Belsky et al., 2017, PMID 28531269). There are also RCTs with ketone-ester approaches (Stubbs et al., 2025, PMID 41313689; Stubbs et al., 2024, PMID 39292659). These are important, but they should be understood more as “marker movement/exploration” than definitive proof of clinical anti-aging effectiveness.

When you interpret the evidence, additional reading can help: Meta-analyses: Evidence & what’s truly supported?.

Epigenetic aging & epitranscriptomic markers: What reviews and the meta-analysis suggest

The evidence base suggests that epigenetic and epitranscriptomic measures are coupled to aging biology, but it does not prove that every change automatically improves health. Arpawnong et al. provides a quantified association through a meta-analytic logic (Arpawnong et al., 2023, PMID 37101297). Wagner et al. frames the epitranscriptome as a relevant but complex marker framework (Wagner et al., 2022, PMID 35908668).

Let’s start with the epigenome. In Arpawong et al., 2023, this is not about a “treatment.” It asks whether a specific genetic burden is associated with older epigenetic age and what factors might mediate that relationship (Arpawong et al., 2023, PMID 37101297). The core message matters for validity: the epigenetic aging measure doesn’t behave like a pure time protocol—it responds to social/behavioral contexts and burden situations. That specific pattern supports biological plausibility.

For the epitranscriptome—RNA modifications and their functional consequences—Wagner et al., 2022 in a systematic review suggests that epitranscriptomic mechanisms may play a role in aging and stress-resistance pathways (Wagner et al., 2022, PMID 35908668). At the same time, the review indirectly highlights a central measurement problem in Geroscience: mechanisms are nested, measurement approaches vary, and the field is not standardized enough that every marker shift can automatically be translated into a clinical advantage.

What does that mean practically?

• Pro: Epigenetic/epitranscriptomic markers are not random; they’re associated with aging biology and burden-related factors.
• Contra: “Coupled” does not equal “causal and clinically relevant for every intervention.”

For your decision-making logic: if you use epigenetic measures, treat them more as a status and hypothesis generator. The evidence in this list answers reasonably well that certain marker families are relevant—but it answers less well which precise marker segment, for which intervention, in which magnitude, leads to which outcome.

Multimorbidity as an endpoint: Biomarkers, value, and limits from the systematic overview

Multimorbidity biomarkers can reflect “disease burden” better than pure chronological age, but they are not automatically validated surrogate endpoints for anti-aging effectiveness. This is shown by the systematic overview of Zazzara et al., 2025: marker clusters are described as recurring patterns for multimorbidity (Zazzara et al., 2025, PMID 40816451).

In the Geroscience debate there is a tension: some markers are intended to measure aging “over time,” while others are meant to reflect “functional and pathological reality.” Multimorbidity is a pragmatic endpoint in this sense because it often aligns more closely with clinical status than a single molecular marker.

Zazzara et al., 2025 compiles studies on multimorbidity biomarkers and discusses that marker clusters may reflect disease burden rather than “just chrono-age” (Zazzara et al., 2025, PMID 40816451). Methodologically, that makes sense: inflammation, metabolic changes, and immunologic dysregulation often occur together across multiple conditions. Therefore, clusters can plausibly be informative, whereas a single “aging measure” might be too one-dimensional.

However, the limitations remain important:

• Systematic reviews often show consistency in occurrence of a biomarker or cluster—not necessarily causality.
• Even if a cluster predicts multimorbidity, it is unclear whether an intervention that changes the cluster will automatically improve clinical multimorbidity.

From this, you can derive a clear interpretation level:

• If a biomarker cluster is associated with multimorbidity, it can be considered useful as a risk context and monitoring tool.
• Whether it serves as a surrogate endpoint for clinical benefit remains, in general, limited by the evidence base.

If you read such biomarkers as a “Geroscience report,” avoid a common misinterpretation: “Marker correlates → intervention works clinically.” That chain is not established in all cases by RCTs or corresponding surrogate validation. This “gap profile” should be kept in mind when selecting what to measure.

Interventions and marker shifts: Calorie restriction, ketone esters, and early inflammation-driven strategies

For intervention effects, the list contains RCT and pilot/concept data, but evidence strength varies depending on the target outcome. Calorie restriction is linked—via CALERIE analyses—to changes in the rate of biological aging (Belsky et al., 2017, PMID 28531269). Ketone esters show exploratory RCT/pilot data on function and tolerability (Stubbs et al., 2025, PMID 41313689; Stubbs et al., 2024, PMID 39292659). Inflammation-driven Geroscience mechanisms are described via a trial concept (Sattui et al., 2026, PMID 41518612).

Calorie restriction (CALERIE context): Belsky et al., 2017 analyzes CALERIE Biobank data in an RCT context and reports that the rate of biological aging in analyses under calorie restriction may change (Belsky et al., 2017, PMID 28531269). The key point is interpretation: “changes” in these analyses usually involve a biological score or a rate estimate, not automatically long-term clinical outcomes. Even so, it is a relatively strong argument that measures move in a Geroscience-relevant direction, not only associationally but potentially in an intervention-sensitive way.

Ketone esters (bis-octanoyl (R)-1,3-butanediol): In Stubbs et al., 2025, daily bis-octanoyl (R)-1,3-butanediol is studied in a randomized, double-blind, placebo-controlled trial in healthy older adults; the study reports exploratory function and quality-of-life outcomes (Stubbs et al., 2025, PMID 41313689). In essence, it addresses: can a ketone ester approach be meaningfully measured and tolerated, and is there a trend in relevant endpoints? In this list, the study data should be understood as “embedded exploration,” not as a final anti-aging truth.

Additionally, there is a pilot study concept/protocol for a ketone-ester-based approach targeting frailty through immunometabolic Geroscience mechanisms (Stubbs et al., 2024, PMID 39292659). This addresses safety, tolerability, and feasibility—important steps, but they do not replace clinical efficacy evidence.

Inflammation-driven strategies (RIGHT trial concept): Sattui et al., 2026 describes the “Reducing Inflammation for Greater Health Trial (RIGHT)” as a concept, rationale, and design (Sattui et al., 2026, PMID 41518612). Since this is a design/concept paper, the list does not report robust efficacy/safety endpoints as outcomes. Still, it shows that the Geroscience “inflammation” mechanism direction is being translated seriously into an RCT framework.

Lifestyle remains the first lever: Even if ketone esters are interesting, the evidence for “which everyday actions” move markers and which improve outcomes that you can measure clinically is often broader than for any single supplement. For a methodological orientation to lifestyle evidence paths, you can additionally look at the evidence strictness for circadian factors in Circadian rhythm: Effects & evidence (what’s supported).

Mandatory clarification on dosing & safety

The complete dosing and safety framework you requested (range, timing, contraindications, interactions) cannot be reliably extracted from the study list provided here: the listed sources name study designs, but—within your prompt—without the relevant details on dosing ranges and safety outcomes. To avoid inventing information, I will therefore not provide specific mg/g ranges, timing windows, or contraindications. For ketone-ester-related safety questions, you should check the full texts directly in the sections on dosage, adverse events, and exclusion criteria (Stubbs et al., 2025, PMID 41313689; Stubbs et al., 2024, PMID 39292659).

Study overview: What the 7 studies (partly) show—and what remains open

The list combines association reviews, systematic overviews, and intervention proximity. That creates a good picture of which marker families are plausible and which interventions might influence markers/outcomes—yet definitive clinical anti-aging conclusions cannot be drawn from the available work.

What remains open (and why it matters):

• Magnitude: How much can markers move without anything clinical happening (or vice versa)? Reviews often address this only indirectly.
• Duration: How long do marker changes need before they produce outcome signals? This is especially relevant for epigenetic measures, because dynamics and measurement variability can be heterogeneous.
• Surrogate validation: Multimorbidity markers show closeness to disease, but the list does not automatically prove they are reliable surrogates for real health gains (Zazzara et al., 2025, PMID 40816451).
• Generalizability: Ketone esters and calorie restriction are two very different intervention types. Translating marker movement into a “general anti-aging effect” remains limited in current evidence as long as clinical endpoints and time horizons are not consistently aligned.

Bottom line: What you should take from this

• Epigenetic and epitranscriptomic markers are plausibly coupled to aging biology, but each individual marker change is not yet automatically a clinical benefit. (Arpawong et al., 2023, PMID 37101297; Wagner et al., 2022, PMID 35908668)
• Multimorbidity biomarkers can reflect disease burden better than chrono-age—yet the surrogate effect for an anti-aging outcome is not automatically established. (Zazzara et al., 2025, PMID 40816451)
• Intervention effects are present in the list (calorie restriction in the CALERIE context; ketone esters in RCT/pilot proximity), but the clinical relevance and the proper interpretation of marker changes are not yet definitively clarified. (Belsky et al., 2017, PMID 28531269; Stubbs et al., 2025, PMID 41313689; Stubbs et al., 2024, PMID 39292659)
• Lifestyle remains the first lever: it broadly targets inflammation, metabolic state, and circadian regulation, while Geroscience supplement evidence in this list is mostly exploratory or conceptual.

If you want, as a next step I can create a “marker checklist” for which metrics to interpret for which goals (risk monitoring, frailty mechanisms, inflammatory state, epigenetic status diagnostics)—strictly aligned with the study families named above.